Alantra has advised IK Investment Partners, Dr. Clemens Künzer and management on the sale of APOSAN to Santé Cie Group

Jul 2020

Sell-side advisory

Frankfurt, 29 July 2020 – Alantra, a global leader in mid-market investment banking and asset management, has advised IK Investment Partners, Dr. Clemens Künzer and management on the sale of Germany’s leading pharmaceutical homecare player APOSAN (“APOSAN” or “the Company”) to French home medical assistance player Santé Cie Group, majority-owned by Ardian. The transaction is subject to the approval of the German antitrust authorities.

Founded in 1991, APOSAN is a leading specialised homecare provider in the field of outpatient parenteral antibiotic therapy, one of the fastest growing segments in the German home care market, as well as parenteral & enteral nutrition and ophthalmic injectables, covering the full homecare value chain from pharmaceutical compounding to care delivery. APOSAN is headquartered in Cologne, Germany, and serves over 15,000 patients per year.

Created in 2016, Santé Cie is the third largest home healthcare provider in France, through its two operating networks Elivie and Asdia. The company supports over 160,000 homecare patients in France, covering a wide range of therapeutic segments including perfusion, nutrition, insulin therapy, the treatment of Parkinson’s disease, respiratory assistance and wound treatment and healing. Santé Cie has over 1,700 employees across 80 agencies throughout France, through its Elivie and Asdia networks.

Anders Petersson, Managing Partner at IK Investment Partners, said: “APOSAN has truly become the undisputed leader in the German pharmaceutical homecare market since we first partnered with the Company in 2016. It has been a pleasure working with APOSAN and its management team and we wish them all the best on their continued journey. We would also like to take the opportunity to thank the Alantra team for the excellent advice and close guidance in all facets throughout this transaction.”

Wolfram Schmerl, Managing Partner at the Frankfurt office of Alantra, highlighted: “It was great to support the shareholders on this exciting transaction, which marks our eighth deal with IK Investment Partners as a client in recent years. Having previously advised IK Investment Partners on the acquisition of APOSAN in 2016, we have closely followed APOSAN’s continued success story. We are delighted for APOSAN that in Santé Cie, the Company has found a reliable partner to build on their existing expertise and complementary product offerings to further expand outpatient therapy indications and services together.”

Christopher Jobst, Director at the Frankfurt office of Alantra, added: “We are thankful to have been given the opportunity to assist on this sell-side assignment and we would like to thank also the entire management for the great working spirit and joint efforts in order to find a new partner for APOSAN.”